Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Clinical trial NCT04687241 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04687241
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-30
- Primary completion
- 2024-07-08
- Enrollment
- 192
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.